# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-29T13:22:55.683741

---

**Idea Fidelity**  
The paper largely adheres to the original idea manifest. It focuses on the dosage-strength composition of oxycodone shipments using ARCOS data, centers on Florida’s HB 7095/pill mill crackdown, and employs high-dose share as the novel outcome. The data source (DEA ARCOS transactions) and key policy timeline (July 2011 enforcement) are incorporated. However, two elements from the manifest are underdeveloped. First, the manifest emphasized spillovers into Georgia and Alabama, yet the paper treats those states solely as controls without assessing whether Florida’s crackdown induced measurable cross-border adjustments in those neighbors. Second, the manifest suggested broader staggered PDMP variation (across 2006–2012) as a potential extension, but the paper sticks to the Florida case alone and does not revisit that broader staggered PDMP design. These omissions should be clarified as intentional scope choices rather than oversights.

---

**Summary**  
The paper documents how Florida’s 2010–2011 pill mill crackdown altered the dosage-strength composition of oxycodone shipments, not just their volume. Using DEA ARCOS transaction data aggregated to county-months for Florida and neighboring Georgia/Alabama, the author(s) construct a high-dose (≥30mg) oxycodone share and show that, in pill-weighted specifications, the crackdown reduced this share by about 9 percentage points. An event study portrays a “boom” phase prior to enforcement and a “bust” phase afterwards, suggesting that the policy specifically dismantled the diversion-heavy high-dose channel.

---

**Essential Points**

1. **Parallel Trends and Identification** – The positive pre-treatment coefficients in the event study raise concerns about whether the Phillips-style difference-in-differences comparison identifies the causal effect of HB 7095. The paper interprets the pre-trend as the natural boom of pill mills, but without a credible control for that rising trajectory (e.g., flexible trends or synthetic control), the “reversal” could reflect regression to the mean or concurrent shocks (e.g., national DEA pressure) rather than the law. Please show that the results are robust when allowing for county-specific linear/quadratic trends, or re-estimate using methods that explicitly model the boom-bust dynamics (e.g., synthetic control, stacked event studies with leads/lags flexibly modeled, or a RITS framework). Without this, the key identification assumption remains untested.

2. **Control Group Composition and Spillovers** – The control group is limited to Georgia and Alabama, but both could have experienced spillovers from Florida’s crackdown (e.g., diversion networks relocating across the border) or their own policy shifts during 2006–2012. Moreover, the pill-weighting means that a few high-volume Florida counties dominate the estimate while low-volume Florida counties wash out in the unweighted sample. The paper should (i) provide more evidence that Georgia/Alabama were unaffected by Florida’s policy (e.g., no simultaneous regulatory changes, no detectable increases in high-dose share), and (ii) consider expanding the control set (e.g., additional Southern states without similar laws) or constructing a synthetic control to better isolate Florida’s counterfactual path. If spillovers exist, the estimated effect may understate the true causal impact, or the control may not accurately represent what would have happened absent HB 7095.

3. **Inference with Few Clusters and Weighting** – With only three state-level clusters, state-clustered standard errors are unreliable, and the permutation test is limited to {FL, GA, AL}, yielding a minimum two-sided \(p\)-value of 1/3. The paper relies heavily on the pill-weighted estimate that gives disproportionate influence to a few counties, which exacerbates the concern. Please either (a) weight inference by county-level clusters or use heteroskedasticity-robust standard errors in combination with wild cluster bootstrap that respects the few-cluster context, or (b) report sensitivity to alternative inference approaches (e.g., use county-level clustering with Conley spatial corrections, nonparametric bootstrap within counties). At a minimum, explicitly describe how the pill-weighting interacts with the permutation test and what that implies for the reliability of \(p\)-values.

---

**Suggestions**

- **Mechanism/Alternative Channels**  
  The interpretation hinges on high-dose pills being the diversion channel. The paper could strengthen this by connecting shipment-level composition to post-treatment outcomes that diverters value (e.g., cash vs. insurance dispensing, anonymous pharmacies). For example, if the ARCOS data identify buyer types (pharmacies vs. practitioners), show that the composition shift is concentrated where diversion was plausible (e.g., non‑retail buyers). Linking the high-dose share shift to subsequent mortality or law enforcement actions could help demonstrate that the dosage shift indeed tracked diverted supply.

- **Additional Outcomes and Robustness**  
  Beyond the high-dose share and average mg, the paper hints at an oxycodone/(oxycodone+hydrocodone) ratio. Expanding this to capture other formulation shifts (e.g., tablets vs. capsules, immediate vs. extended release if available) would enrich the story about composition. Also, the 30mg cutoff is sensible, but presenting a figure showing the full dosage distribution pre- and post-law (perhaps via cumulative distribution functions or histograms) would help readers visualize the reallocation within the distribution rather than relying on binary thresholds. In robustness checks, consider estimating the effect on the share of prescriptions dispensed in cash (if linked) or matching with patent enforcement events to rule out other concurrent shocks.

- **Event Study Presentation**  
  The event study currently reports quarterly point estimates with standard errors but no graphical representation. Displaying these coefficients in a figure with confidence ribbons would make it easier to evaluate pre-trend behavior, especially the positive pre-trend that is central to the narrative. Additionally, consider adding a panel that shows how treated and control counties’ raw high-dose shares evolve over time, which could help readers judge whether the control group is plausibly on a similar trajectory prior to 2011.

- **Discussion of External Validity**  
  The paper concludes with policy implications for monitoring dosage composition. To support this, you might discuss how feasible it is to track high-dose share in real time (e.g., availability of PDMP or ARCOS data) and whether dosage monitoring could complement existing quantity-based surveillance. Discuss limitations: if future diversion networks shift to new dosages or substances, how would the proposed metric adapt?

- **Clarify the Donut and Restricted Pre-period**  
  The restricted pre-period (2009+) and donut checks yield larger (in magnitude) estimates. Please clarify whether these regressions still include the same control group and how the different pre-period window affects the pre-trend behavior. If the inverted boom is driving the result, why does the restriction strengthen the estimate rather than attenuate it? Also, be explicit about the definition of “transition period” in the donut specification—e.g., was October 2010 treated as treated or excluded entirely?

- **Permutation Inference Narrative**  
  You note that the permutation test yields a minimum \(p=1/3\) and that Florida produces the “most extreme” effect. Since this is substantially above conventional significance levels, it would help to report the full permutation distribution (or at least the values for the other states) and explain why the asymmetry still provides confidence in the result. Perhaps supplement the permutation test with a subsample of counties (e.g., using random subsets) to demonstrate that the effect persists beyond the state-level classification.

- **Data Handling**  
  The appendix mentions that 4.2% of county-month-dosage rows had missing dosage strength and were excluded. Please describe whether the missingness is random or correlated with certain buyers, counties, or dosage strengths. If the missingness is systematic, it may bias the high-dose share. Consider, if feasible, multiple imputation or bounding the estimates to show the effect is robust to different assumptions about the missing data.

- **Clarify Weighting Rationale**  
  The rationale for pill-weighting is that higher-volume counties are where the policy bite was largest. However, weighting also means that the result is driven by a subset of counties and could be mechanically sensitive to outliers. A complementary approach would be to estimate the effect separately for the top decile of pill-volume counties and the rest, or to report the distribution of weights. Furthermore, explain whether weights are normalized (do they sum to one each period) and how missing data in low-volume counties affect the estimation.

- **Policy Timing and Multiple Interventions**  
  HB 7095 included multiple provisions phased in at different dates, including pain clinic registration, physician dispensing limits, and the PDMP. The paper treats July 2011 as the enforcement start but the law also had an October 2010 component. Provide justification (perhaps from legislative records) for why July 2011 is the appropriate treatment date for the composition shift. You might also explore whether earlier enforcement steps produced partial effects by including additional leads/lags or interacting the policy with time to capture a gradual implementation.

- **Link to Broader Literature**  
  Several papers study the Florida pill mill crackdown’s effects on mortality and substitution; you might cite and contrast with those findings more explicitly (e.g., \citet{alpert2018supply}, \citet{evans2019reformulation}) to situate your composition story in the broader narrative. The discussion could also mention how this dosage-focused analysis complements studies that look at transitions to heroin/fentanyl, by showing the within-prescription market dynamics.

By addressing these points, the paper would better establish the causal link between policy and dosage composition, strengthen the credibility of its counterfactuals, and provide clearer policy takeaways about monitoring diversion via formulation mix.
